Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2-induced splenic enlargement

M A Pozniak1, P S Christy, M R Albertini

  • 1Department of Radiology, University of Wisconsin Hospital and Clinics, Madison 53792, USA.

Cancer
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Correction to Lancet Oncol 2015; 16: 738. Anti-EGFR monoclonal antibodies in lung cancer treatment.

The Lancet. Oncology·2015
Same author

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

European journal of cancer (Oxford, England : 1990)·2013
Same author

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

British journal of cancer·2013

Interleukin-2 (IL-2) immunotherapy for cancer can cause spleen enlargement. This splenomegaly is likely a side effect of IL-2 treatment, not a sign of cancer progression.

Area of Science:

  • Oncology
  • Immunotherapy
  • Radiology

Background:

  • Splenomegaly in cancer patients often suggests tumor spread.
  • However, splenic enlargement has been observed in patients receiving interleukin-2 (IL-2) immunotherapy, even without splenic metastases.
  • This study investigated spleen size changes in patients undergoing IL-2 therapy.

Purpose of the Study:

  • To characterize the changes in spleen size during and after interleukin-2 (IL-2) immunotherapy.
  • To differentiate between splenomegaly due to tumor progression and IL-2 therapy side effects.

Main Methods:

  • Retrospective review of computed tomography (CT) scans from 42 patients treated with IL-2 for nonhematologic malignancies.
  • Measurement of splenic index by a single, blinded reader before, during, and after IL-2 therapy.

Related Experiment Videos

Main Results:

  • The mean splenic index significantly increased by 64.1% during IL-2 therapy (646 cm³ to 1059 cm³; P < 0.0001).
  • Elevated splenic index persisted after completion of IL-2 treatment (1112 cm³).

Conclusions:

  • Splenomegaly observed during IL-2 therapy for nonhematologic malignancies is likely a consequence of the treatment.
  • This splenic enlargement is unlikely to indicate tumor progression.